Modern approaches to optimization of the risk of syndrome of massive tumor cytolysis prevention
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Гематология: национальное руководство / под ред. О.А. Рукавицына. – М.: ГЭОТАР Медиа, 2015. – 776 с.
Клиническая онкогематология: руководство для врачей / под ред. М.А. Волковой. – 2 е изд., перераб. и доп. – М.: АОА «Издательство «Медицина», 2007. – 1120 с.
Коврыгина А.М. Лимфома Ходжкина и крупноклеточные лимфомы / А.М. Коврыгина, Н.А. Пробатова. – М.: ООО «Медицинское информационное агенство», 2007. – 216 с.
Acute tumor lysis syndrome following a singl dose corticosteroids in children with acute lymphoblastic leukemia / A. Duzova, M. Cetin, F. Gumruk et al. // Eur. J. Haematol. – 2001. – Vol. 66, No 2. – P. 404–407.
Adiyanti S.S. Acute kidney injury (AKI) biomarker / S.S. Adiyanti, T. Loho // Acta Med. Indones. – 2012. – No 1. – P. 200–208.
Cario M.S. Tumor lysis syndrome: new therapeutic strategies and classification / M.S. Cario, M. Bishop // Br. J. Hematol. – 2004. – Vol. 127, No 1. – P. 3–11.
Clinical biomarkers in kidney diseases / F. Bonomini, E. Foglio, L.F. Rodella, R. Rezzani // Front. Biosci. – 2010. – No 2. – P. 591–615.
Fulminant tumor lysis syndrome in acute myelogenous leukemia with inv (16)(p13;q22) / M.D. Seftel, H. Bruyere, M. Copland et al. // Eur. J. Hematol. – 2002. – Vol. 69, No 2. – Р. 193–199.
Hande K.R. Acute tumor lysis syndrome in patients with high grade non hodgkin`s lymphoma / K.R. Hande, G.G. Garrow // Am. J. Med. – 1993. – Vol. 94, No 1. – Р. 133–139.
Hyperleukocytic leukemias: a review of pathophysiology, clinical presentation and management / P. Porcu, L.D. Cripe, E.W. Ng et al. // Leukemia and Lymphoma. – 2000. – Vol. 39, No 1. – P. 1–18.
Ivanov D.D. Next step in chronic kidney disease therapy / D.D. Ivanov // Kidneys. – 2016. – No 2 (16). – P. 10–13.
Jena S. Tumor lysis syndrome / Jena S. // Semin.Oncol. – 2001. – Vol. 38, (suppl.10). – P. 4–8.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease // Kidney inter., Suppl. – 2012. – Vol. 2 / [Електронний ресурс]. — Режим доступу: http://www.kidney-international.org&2012 KDIGO340
Novik A. Patient reported outcomes in hematology: guidelines / Ed.: A. Novik, S. Salek, T. Ionova. – Genoa: Forum F service editore, 2012. – 196 p.
Rasburicase (recombinant urate oxidase) for the treatment of hyperuricemia in patients with cancer / A. Bosly, A. Sonnet, C.R. Pinkerton et al. // Cancer. – 2003. – Vol. 98, No 5. – P. 1048–1054.
Rx index. Vademecum. – Kyiv: Pharmacevt Praktik, 2015. – 1296 p.
Sharma A. Renal functional reserve and renal recovery after acute kidney injury / A. Sharma, M.J. Mucino, C. Ronco // Nephron. Clin. Pract. – 2014. – Vol. 127, No 1. – P. 94–100.
Sile S. Acute renal failure secondary to spontaneous acute tumor lysis syndrome in myelofibrosis / S. Sile, B.M. Wall / Am. J. Kidney Dis. – 2001. – Vol. 38, No 4. – E21.
Spontaneous acute tumor lysis syndrome with advanced gastric cancer / I.S. Woo, J.S. Kim, M.J. Part et al. // J. Korean Med. Sci. – 2001. – Vol. 16, No 1. – P. 115–118.
Tumor lysis syndrome: pathogenesis and treatment / D.P. Jones, H. Mahmoud et al. // Pediatr. Nephrol. – 2000. – Vol. 9. – P. 206–212.
Validation of cell cycle arrest biomarkers for acute kidney injury using clinical adjudication / A. Bihorac, L.S. Chawla, A.D. Shaw et al. // Am. J. Respir. Crit. Care. Med. – 2014. – Vol. 189, No 4. – P. 932–934.
